Eton Pharmaceuticals (ETON) Share-based Compensation (2018 - 2025)

Eton Pharmaceuticals (ETON) has 8 years of Share-based Compensation data on file, last reported at -$4.1 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 87.38% year-over-year to -$4.1 million; the trailing twelve-month figure through Dec 2025 stood at -$5.4 million (down 617.64% YoY), and the FY2025 full-year result was $5.0 million, down 7.33% from the prior year.
• Share-based Compensation declined to -$4.1 million in Q4 2025, from $5.8 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $8.5 million in Q2 2025 to a low of -$4.1 million in Q4 2025.
• A 5-year average of $2.0 million and a median of $917500.0 in 2022 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 216300.0% in 2024 and jumped 819.12% in 2025, its largest moves.
• Tracing ETON's Share-based Compensation over 5 years: stood at $863000.0 in 2021, then rose by 2.67% to $886000.0 in 2022, then tumbled by 100.11% to -$1000.0 in 2023, then slumped by 216300.0% to -$2.2 million in 2024, then slumped by 87.38% to -$4.1 million in 2025.
• Business Quant data shows ETON's Share-based Compensation at -$4.1 million in Q4 2025, $5.8 million in Q3 2025, and $8.5 million in Q2 2025.